Literature DB >> 30599179

Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies.

Piyoosh Sharma1, Pavan Srivastava1, Ankit Seth1, Prabhash Nath Tripathi1, Anupam G Banerjee1, Sushant K Shrivastava2.   

Abstract

AD is a progressive neurodegenerative disorder and a leading cause of dementia in an aging population worldwide. The enormous challenge which AD possesses to global healthcare makes it as urgent as ever for the researchers to develop innovative treatment strategies to fight this disease. An in-depth analysis of the extensive available data associated with the AD is needed for a more comprehensive understanding of underlying molecular mechanisms and pathophysiological pathways associated with the onset and progression of the AD. The currently understood pathological and biochemical manifestations include cholinergic, Aβ, tau, excitotoxicity, oxidative stress, ApoE, CREB signaling pathways, insulin resistance, etc. However, these hypotheses have been criticized with several conflicting reports for their involvement in the disease progression. Several issues need to be addressed such as benefits to cost ratio with cholinesterase therapy, the dilemma of AChE selectivity over BChE, BBB permeability of peptidic BACE-1 inhibitors, hurdles related to the implementation of vaccination and immunization therapy, and clinical failure of candidates related to newly available targets. The present review provides an insight to the different molecular mechanisms involved in the development and progression of the AD and potential therapeutic strategies, enlightening perceptions into structural information of conventional and novel targets along with the successful applications of computational approaches for the design of target-specific inhibitors.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30599179     DOI: 10.1016/j.pneurobio.2018.12.006

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  45 in total

1.  Neuroprotective and Antioxidant Role of Oxotremorine-M, a Non-selective Muscarinic Acetylcholine Receptors Agonist, in a Cellular Model of Alzheimer Disease.

Authors:  Giuseppa Mudò; Valentina Di Liberto; Domenico Nuzzo; Monica Frinchi; Costanza Giardina; Miriana Scordino; Mariachiara Zuccarini; Chiara De Simone; Marta Di Carlo; Natale Belluardo
Journal:  Cell Mol Neurobiol       Date:  2022-09-03       Impact factor: 4.231

2.  A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer's disease.

Authors:  Marcella Catania; Laura Colombo; Stefano Sorrentino; Alfredo Cagnotto; Jacopo Lucchetti; Maria Chiara Barbagallo; Ilaria Vannetiello; Elena Rita Vecchi; Monica Favagrossa; Massimo Costanza; Giorgio Giaccone; Mario Salmona; Fabrizio Tagliavini; Giuseppe Di Fede
Journal:  Mol Psychiatry       Date:  2022-08-26       Impact factor: 13.437

3.  Blood-Brain Barrier Permeability Study of Potential Neuroprotective Compounds Recovered From Plants and Agri-Food by-Products.

Authors:  José David Sánchez-Martínez; Alberto Valdés; Rocio Gallego; Zully Jimena Suárez-Montenegro; Marina Alarcón; Elena Ibañez; Gerardo Alvarez-Rivera; Alejandro Cifuentes
Journal:  Front Nutr       Date:  2022-06-16

4.  4-Aminoquinoline-Based Adamantanes as Potential Anticholinesterase Agents in Symptomatic Treatment of Alzheimer's Disease.

Authors:  Katarina Komatović; Ana Matošević; Nataša Terzić-Jovanović; Suzana Žunec; Sandra Šegan; Mario Zlatović; Nikola Maraković; Anita Bosak; Dejan M Opsenica
Journal:  Pharmaceutics       Date:  2022-06-20       Impact factor: 6.525

5.  Chrysophanol improves memory ability of d-galactose and Aβ25-35 treated rat correlating with inhibiting tau hyperphosphorylation and the CaM-CaMKIV signal pathway in hippocampus.

Authors:  Ting Ye; Xinquan Li; Peng Zhou; Shu Ye; Huawu Gao; Rupeng Hua; Junlong Ma; Yan Wang; Biao Cai
Journal:  3 Biotech       Date:  2020-02-13       Impact factor: 2.406

Review 6.  Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels.

Authors:  Sara Cunha; Ben Forbes; José Manuel Sousa Lobo; Ana Catarina Silva
Journal:  Int J Nanomedicine       Date:  2021-06-29

7.  Synthesis, molecular docking, and biological evaluation of novel 2-pyrazoline derivatives as multifunctional agents for the treatment of Alzheimer's disease.

Authors:  Oya Unsal-Tan; Tuba Tüylü Küçükkılınç; Beyza Ayazgök; Ayla Balkan; Keriman Ozadali-Sari
Journal:  Medchemcomm       Date:  2019-05-09       Impact factor: 3.597

Review 8.  Toxicology and pharmacology of synthetic organoselenium compounds: an update.

Authors:  Cristina W Nogueira; Nilda V Barbosa; João B T Rocha
Journal:  Arch Toxicol       Date:  2021-04-01       Impact factor: 6.168

Review 9.  Thioredoxin-interacting protein (TXNIP) as a target for Alzheimer's disease: flavonoids and phenols.

Authors:  Meng Zhang; Guanhua Hu; Nan Shao; Yunpeng Qin; Qian Chen; Yan Wang; Peng Zhou; Biao Cai
Journal:  Inflammopharmacology       Date:  2021-08-04       Impact factor: 4.473

Review 10.  DNA damage and regulation of protein homeostasis.

Authors:  Tanya T Paull
Journal:  DNA Repair (Amst)       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.